{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T11:45:50Z","timestamp":1648899950260},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00393-021-01144-7","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:03:11Z","timestamp":1641582191000},"page":"118-124","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neues zu Therapiestrategien bei der rheumatoiden Arthritis"],"prefix":"10.1007","volume":"81","author":[{"given":"Klaus","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"1144_CR1","unstructured":"Deutsches Rheumaforschungszentrum Daten der Kerndokumentation 2018 (noch unpubliziert) Abgerufen am 30.9.2021"},{"key":"1144_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab398","author":"B Combe","year":"2021","unstructured":"Combe\u00a0B, Rincheval\u00a0N, Berenbaum\u00a0F et al (2021) Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab398","journal-title":"Rheumatology"},{"issue":"Suppl. 2","key":"1144_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et al (2018) S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z\u00a0Rheumatol 77(Suppl. 2):35\u201353","journal-title":"Z Rheumatol"},{"issue":"Suppl. 1","key":"1144_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00393-020-00775-6","volume":"79","author":"M Schneider","year":"2020","unstructured":"Schneider\u00a0M, Baseler\u00a0G, Funken\u00a0O et\u00a0al (2020) Management der fr\u00fchen rheumatoiden Arthritis. Interdisziplin\u00e4re Leitlinie. Z\u00a0Rheumatol 79(Suppl. 1):1\u201338","journal-title":"Z Rheumatol"},{"key":"1144_CR5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1093\/rheumatology\/kez635","volume":"59","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou\u00a0E, Norton\u00a0SJ, Carpenter\u00a0L et\u00a0al (2020) Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. Rheumatology 59:2381\u20132391","journal-title":"Rheumatology"},{"key":"1144_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor\u00a0C, Capell\u00a0H, Stirling\u00a0A et al (2004) Effect of a\u00a0treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a\u00a0single-blind randomised controlled trial. Lancet 364:263\u2013269","journal-title":"Lancet"},{"key":"1144_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SMM Verstappen","year":"2007","unstructured":"Verstappen\u00a0SMM, Jacobs\u00a0JWG, van der Veen\u00a0MJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66:1443\u20131449","journal-title":"Ann Rheum Dis"},{"key":"1144_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","volume":"388","author":"JW Bijlsma","year":"2016","unstructured":"Bijlsma\u00a0JW, Welsing\u00a0PM, Woodworth\u00a0TG et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343\u2013355","journal-title":"Lancet"},{"key":"1144_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","volume":"146","author":"YPM Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman\u00a0YPM, de Vries-Bouwstra\u00a0JK, Allaart\u00a0CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146:406\u2013415","journal-title":"Ann Intern Med"},{"key":"1144_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/annrheumdis-2019-216819","volume":"79","author":"S Ramiro","year":"2020","unstructured":"Ramiro\u00a0S, Landewe\u00a0RBM, van der Heijde\u00a0D et al (2020) Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann Rheum Dis 79:453\u2013459","journal-title":"Ann Rheum Dis"},{"key":"1144_CR11","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1093\/rheumatology\/kez674","volume":"59","author":"U Sundin","year":"2020","unstructured":"Sundin\u00a0U, Aga\u00a0AB, Skare \u00d8 et\u00a0al (2020) Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2\u00a0years in early rheumatoid arthritis. Rheumatology 59:2550\u20132555","journal-title":"Rheumatology"},{"key":"1144_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF Van Vollenhoven","year":"2009","unstructured":"Van Vollenhoven\u00a0RF, Ernestam\u00a0S, Geborek\u00a0P et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1\u2011year results of a\u00a0randomised trial. Lancet 374:459\u2013466","journal-title":"Lancet"},{"key":"1144_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","volume":"71","author":"K Wevers-deBoer","year":"2012","unstructured":"Wevers-deBoer\u00a0K, Visser\u00a0K, Heimans\u00a0L et al (2012) Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 71:1472\u20131477","journal-title":"Ann Rheum Dis"},{"key":"1144_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","volume":"76","author":"P Verschueren","year":"2017","unstructured":"Verschueren\u00a0P, de Cock\u00a0D, Corluy\u00a0L et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a\u00a0treat-to-target approach: 1\u2011year results of CareRA, a\u00a0randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511\u2013520","journal-title":"Ann Rheum Dis"},{"key":"1144_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen\u00a0JS, Aletaha\u00a0D, Bijlsma\u00a0JW et\u00a0al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631\u2013637","journal-title":"Ann Rheum Dis"},{"key":"1144_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.41720","volume":"73","author":"H K\u00e4llmark","year":"2021","unstructured":"K\u00e4llmark\u00a0H, Einarsson\u00a0JT, Nilsson\u00a0JA et\u00a0al (2021) Sustained remission in patients with rheumatoid arthritis on triple therapy compared to biological therapy\u2014a\u00a0Swedish nationwide register study. Arthritis Rheum 73:1135\u20131144","journal-title":"Arthritis Rheum"},{"key":"1144_CR17","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","volume":"58","author":"PDH Hamann","year":"2019","unstructured":"Hamann\u00a0PDH, Pauling\u00a0JD, McHugh\u00a0N et al (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology 58:2162\u20132169","journal-title":"Rheumatology"},{"key":"1144_CR18","first-page":"205","volume":"59","author":"JT Einarsson","year":"2020","unstructured":"Einarsson\u00a0JT, Willim\u00a0M, Saxne\u00a0T et\u00a0al (2020) Secular trends of sustained remission in rheumatoid arthritis, a\u00a0nationwide study in Sweden. Rheumatology 59:205\u2013212","journal-title":"Rheumatology"},{"key":"1144_CR19","doi-asserted-by":"publisher","first-page":"e0214981","DOI":"10.1371\/journal.pone.0214981","volume":"14","author":"YK Sung","year":"2019","unstructured":"Sung\u00a0YK, Yoshida\u00a0K, Prince\u00a0FHM et\u00a0al (2019) Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS ONE 14:e214981","journal-title":"PLoS ONE"},{"key":"1144_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13075-020-02368-9","volume":"22","author":"M Verstappen","year":"2020","unstructured":"Verstappen\u00a0M, Niemantsverdriet\u00a0E, Matthijssen\u00a0XME et al (2020) Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Arthritis Res Ther 22:276","journal-title":"Arthritis Res Ther"},{"key":"1144_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett\u00a0G, Emery\u00a0P, Tanaka\u00a0Y et\u00a0al (2016) Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 75:1428\u20131437","journal-title":"Ann Rheum Dis"},{"key":"1144_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.31138\/mjr.31.4.384","volume":"31","author":"H Corominas","year":"2020","unstructured":"Corominas\u00a0H, Millan\u00a0AM, Diaz-Torne\u00a0C (2020) Rheumatoid arthritis: defining clinical and ultrasound deep remission. Mediterr J Rheumatol 31:384\u2013388","journal-title":"Mediterr J Rheumatol"},{"key":"1144_CR23","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/acr.24358","volume":"73","author":"AR Karpes Matusevic","year":"2021","unstructured":"Karpes Matusevic\u00a0AR, Duan\u00a0Z, Zhao\u00a0H et\u00a0al (2021) Treatment sequences after discontinuing a\u00a0tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies. Arthritis Care Res 73:1461\u20131469","journal-title":"Arthritis Care Res"},{"key":"1144_CR24","doi-asserted-by":"publisher","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth\u00a0A, Szabo\u00a0MZ, Kedves\u00a0M et al (2019) Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev 18:102398. https:\/\/doi.org\/10.1016\/j.autrev.2019.102398","journal-title":"Autoimmun Rev"},{"key":"1144_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg\u00a0JE, Brocq\u00a0O, Perdriger\u00a0A et al (2016) Non-TNF-targeted biologic vs a\u00a0second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a\u00a0first anti-TNF drug. A randomized clinical trial. JAMA 316:1172\u20131180","journal-title":"JAMA"},{"key":"1144_CR26","doi-asserted-by":"publisher","first-page":"vii42","DOI":"10.1093\/rheumatology\/key195","volume":"57","author":"M Todoerti","year":"2018","unstructured":"Todoerti\u00a0M, Favalli\u00a0EG, Iannone\u00a0F et\u00a0al (2018) Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a\u00a0modified Italian expert consensus. Rheumatology 57:vii42\u2013vii53","journal-title":"Rheumatology"},{"issue":"10","key":"1144_CR27","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha\u00a0D, Funovits\u00a0J, Keystone\u00a0EC, Smolen\u00a0JS (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56(10):3226\u20133235","journal-title":"Arthritis Rheum"},{"key":"1144_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landewe\u00a0RBM, Bijlsma\u00a0JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"1144_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/art.39946","volume":"69","author":"L Tweehuysen","year":"2017","unstructured":"Tweehuysen\u00a0L, van den Ende\u00a0CH, Beeren\u00a0FMM et\u00a0al (2017) Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a\u00a0biologic agent in rheumatoid arthritis. A systematic review. Arthritis Rheum 69:301\u2013308","journal-title":"Arthritis Rheum"},{"key":"1144_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00220-4","author":"K Tascilar","year":"2021","unstructured":"Tascilar\u00a0K, Hagen\u00a0M, Kleyer\u00a0A et al (2021) Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a\u00a0multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(21)00220-4","journal-title":"Lancet Rheumatol"},{"key":"1144_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","volume":"77","author":"S Henaux","year":"2018","unstructured":"Henaux\u00a0S, Ruyssen-Witrand\u00a0A, Cantagrel\u00a0A et al (2018) Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and metaanalysis. Ann Rheum Dis 77:515\u2013522","journal-title":"Ann Rheum Dis"},{"key":"1144_CR32","doi-asserted-by":"publisher","first-page":"CD010455","DOI":"10.1002\/14651858.CD010455.pub3","volume":"5","author":"LM Verhoef","year":"2019","unstructured":"Verhoef\u00a0LM, van den Bernt\u00a0BJF, van der Maas\u00a0A et al (2019) Down-titration and discontinuation strategies of tumour necrosis factor\u2013blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 5:CD10455. https:\/\/doi.org\/10.1002\/14651858.CD010455.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1144_CR33","first-page":"1023","volume":"79","author":"P Emery","year":"2020","unstructured":"Emery\u00a0P, Burmester\u00a0GR, Naredo\u00a0E et al (2020) Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis 79:1023\u20131030","journal-title":"Ann Rheum Dis"},{"key":"1144_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","volume":"79","author":"E Van Mulligen","year":"2020","unstructured":"Van Mulligen\u00a0E, Weel\u00a0AE, Hazes\u00a0JM et al (2020) Tapering towards DMARD-free remission in established rheumatoid arthritis: 2\u2011year results of the TARA trial. Ann Rheum Dis 79:1174\u20131181","journal-title":"Ann Rheum Dis"},{"key":"1144_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/art.41589","volume":"73","author":"JR Curtis","year":"2021","unstructured":"Curtis\u00a0JR, Emery\u00a0P, Karls\u00a0E et\u00a0al (2021) Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis Rheum 73:759\u2013768","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01144-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-01144-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01144-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T10:19:11Z","timestamp":1646302751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-01144-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-01144-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"5 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Kr\u00fcger: Referenten- und Beraterhonorare von den Firmen AbbVie, Amgen, Biogen, BMS, Celgene, Celltrion, Chugai, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}